News coverage about Nektar Therapeutics (NASDAQ:NKTR) has trended somewhat positive recently, Accern Sentiment Analysis reports. The research firm ranks the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Nektar Therapeutics earned a news sentiment score of 0.21 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.8398166673505 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the media headlines that may have effected Accern Sentiment’s scoring:

Nektar Therapeutics (NASDAQ NKTR) traded up $1.43 during trading hours on Friday, reaching $71.59. The company had a trading volume of 3,687,433 shares, compared to its average volume of 2,220,000. The company has a market capitalization of $11,500.00, a price-to-earnings ratio of -100.83 and a beta of 1.81. Nektar Therapeutics has a 12 month low of $11.41 and a 12 month high of $75.33. The company has a quick ratio of 3.99, a current ratio of 4.14 and a debt-to-equity ratio of 2.91.

Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Tuesday, November 7th. The biopharmaceutical company reported $0.37 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.21 by $0.16. The company had revenue of $152.90 million during the quarter, compared to analyst estimates of $126.50 million. Nektar Therapeutics had a negative return on equity of 190.68% and a negative net margin of 42.08%. The firm’s quarterly revenue was up 321.2% on a year-over-year basis. During the same quarter last year, the company earned ($0.32) earnings per share. equities analysts predict that Nektar Therapeutics will post -0.76 earnings per share for the current year.

A number of research firms have recently commented on NKTR. Mizuho began coverage on Nektar Therapeutics in a report on Tuesday, September 26th. They issued a “buy” rating and a $30.00 price target for the company. Canaccord Genuity reaffirmed a “buy” rating and issued a $80.00 price target (up from $50.00) on shares of Nektar Therapeutics in a report on Wednesday, January 10th. Zacks Investment Research raised Nektar Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday. Roth Capital set a $45.00 price target on Nektar Therapeutics and gave the stock a “buy” rating in a report on Monday, November 13th. Finally, JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $44.00 price target on shares of Nektar Therapeutics in a report on Monday, November 13th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and twelve have given a buy rating to the company. Nektar Therapeutics has a consensus rating of “Buy” and an average target price of $42.50.

In related news, CEO Howard W. Robin sold 83,334 shares of Nektar Therapeutics stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $23.57, for a total transaction of $1,964,182.38. Following the completion of the sale, the chief executive officer now owns 235,838 shares of the company’s stock, valued at $5,558,701.66. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, SVP Stephen K. Doberstein sold 396,323 shares of Nektar Therapeutics stock in a transaction on Wednesday, November 8th. The shares were sold at an average price of $29.00, for a total value of $11,493,367.00. Following the sale, the senior vice president now directly owns 52,016 shares of the company’s stock, valued at approximately $1,508,464. The disclosure for this sale can be found here. Insiders have sold 614,017 shares of company stock valued at $20,587,527 in the last three months. 6.10% of the stock is owned by corporate insiders.

COPYRIGHT VIOLATION NOTICE: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Nektar Therapeutics (NKTR) Stock Price” was first reported by Watch List News and is the sole property of of Watch List News. If you are reading this story on another publication, it was copied illegally and reposted in violation of U.S. and international trademark and copyright law. The original version of this story can be read at

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company that discovers and develops medicines in areas of high unmet medical need. The Company’s research and development pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. It leverages its chemistry platform to discover and design new drug candidates.

Insider Buying and Selling by Quarter for Nektar Therapeutics (NASDAQ:NKTR)

Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with's FREE daily email newsletter.